• ERT and Bioclinica are now Clario. Find out more about our new name, and why we have come together.

Your using an unsupported browser. Please update to a modern browser for a better experience.

Preparing for Phase 1 – Strategies for Success in Advancing Your Drug to First-in-Human Trials

November 17, 2021

Dr. Borje Darpo will be a guest speaker and he will focus on ‘Replacing the thorough QT study with ECG evaluation in first-in-human trials’.


Borje Darpo, MD, PhD

Chief Scientific Officer of Cardiac Safety at Clario

As Clario, formerly ERT’s Chief Scientific Officer, Borje Darpo, MD, PhD oversees Clario’s cardiology services and consults with external customers to ensure the cardiac safety of their compounds in development. He is board-certified in cardiology and internal medicine and has 20 years of experience overseeing projects across all phases of clinical development.